CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Ph 样急性淋巴细胞白血病的治疗：来自中国单一大型中心的真实世界回顾性分析
英文原题：Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
查看英文原题
Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
费城染色体样急性淋巴细胞白血病（Ph样ALL）是ALL的一种高危亚型。本研究回顾性分析70例Ph样ALL患者，是目前该白血病CAR-T 细胞治疗和单倍体相合造血干细胞移植（haplo-HSCT）规模最大的研究。患者中位年龄26岁，中位白细胞计数31.44×10⁹/L。接受化疗、激酶抑制剂（KI）、CAR-T 细胞及异基因HSCT的患者比例分别为19%、30%、46%和61%。KI联合化疗治疗1个月后、CAR-T 治疗后及异基因HSCT后的总缓解率分别为62%、73%和100%。5年无病生存期（DFS）和总生存期（OS）分别为35%和51%；5年累积复发率和非复发死亡率分别为63%和11%。单变量分析显示，异基因HSCT与更好的DFS（P=0.010）和OS（P=0.000）相关。综上，在KI基础上联合化疗或CAR-T 后进行异基因HSCT，是治疗Ph样ALL安全且可行的方法。
展开英文摘要原文
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of ALL.
We retrospectively studied 70 cases with Ph-like ALL and here present the largest study of CAR-T cell treatment and haplo-HSCT for this leukemia. Median age was 26 years and median leukocyte count was 31. 44 10 9 /L. The proportion of patients receiving chemotherapy, KIs, CAR-T cells, and allo-HSCT was 19%, 30%, 46%, and 61%, respectively.
The overall response rate was 62%, 73%, and 100% after one month of KI treatment combined with chemotherapy, CAR-T cell therapy, and allo-HSCT, respectively. Five-year DFS and OS were 35% and 51%, respectively. The five-year cumulative incidence of relapse and non-relapse mortality was 63% and 11%, respectively. Allo-HSCT was associated with a better DFS ( p = 0. 010) and OS ( p = 0. 000) by univariate analysis.
In conclusion, allo-HSCT after KIs together with chemotherapy or CAR-T cell therapy is a safe and feasible treatment modality for Ph-like ALL.
论文信息
- 作者
- Xu GF、Liu LM、Wang M、Zhang ZB、Xie JD、Qiu HY、Chen SN
- 单位
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Collaborative Innovation Center of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, P.R. China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Leukemia & lymphoma2022 Nov
- 原文标识
- PubMed 35748683 · DOI 10.1080/10428194.2022.2090550